glucose oxidase + chloroquine

Glucose oxidase + chloroquine is an experimental combination therapy designed for synergistic cancer treatment, particularly in the context of chemodynamic therapy (CDT) and starvation therapy. The combination utilizes glucose oxidase (GOx), a biologic enzyme that catalyzes the oxidation of glucose into gluconic acid and hydrogen peroxide (H2O2). This process serves two purposes: it depletes the tumor's nutrient supply (starvation therapy) and provides the H2O2 necessary for Fenton-like reactions that generate toxic hydroxyl radicals. Chloroquine (CQ), a small molecule antimalarial drug, is incorporated as an autophagy inhibitor to block the tumor cells' ability to survive the resulting oxidative stress and nutrient deprivation. These components are typically co-loaded into advanced nanoparticle delivery systems, such as hollow mesoporous manganese dioxide (H-MnO2) or silica shells, often functionalized with targeting peptides like iRGD to enhance tumor penetration and delivery efficiency. This approach is currently in the research stage, with significant focus on overcoming therapeutic resistance in pancreatic cancer.

Other names

GOx + CQglucose oxidase and chloroquineH-MnO2/GOX&CQ-iRGD